Abstract
Morbidity and mortality of chronic liver disease are primarily caused by liver cirrhosis and portal hypertension, both of them secondary disorders of progressive liver fibrosis. The main fibrogenic cell type in the liver, the hepatic stellate cell (HSC), is activated and stimulated by several factors, among which the renin-angiotensin-aldosterone system (RAAS) plays a major role. Angiotensin II induces various profibrotic pathways via the angiotensin II receptor type 1 (AT1 receptor) not only in heart and kidney, but also in liver tissue. Stimulation of the AT1 receptor promotes the transformation of the quiescent HSC into the myofibroblast like activated HSC and the synthesis of transforming growth factor- 1 (TGF-7bgr;), the major profibrotic cytokine in the liver. In addition, aldosterone has been suggested to induce profibrotic effects in chronic heart and liver disease. This review focuses on the concept that inhibitors of the RAAS retard or even reverse liver fibrosis and reduce portal hypertension. Angiotensin converting enzyme (ACE) inhibitors, AT1 receptor antagonists, and aldosterone antagonists have been demonstrated to reduce the proliferation of HSC, to decrease the synthesis of profibrotic molecules, and to have the potential to improve liver fibrosis. However, side-effects such as systemic hypotension may impair the clinical application of RAAS inhibitors in patients with liver cirrhosis and portal hypertension. Also, efficacy may be limited by the downregulation of AT1 receptors in advanced fibrosis, which has been observed in animal and human studies. Randomized clinical studies are essential to evaluate, whether this approach is beneficial in patients with chronic liver disease and progressive fibrosis.
Keywords: Liver fibrosis, portal hypertension, renin-angiotensin-aldosterone system, AT1 receptor blocker, ACE inhibitor, aldosterone antagonist, aliskiren
Current Medicinal Chemistry
Title: Impact of Inhibitors of the Renin-Angiotensin-Aldosterone System on Liver Fibrosis and Portal Hypertension
Volume: 13 Issue: 30
Author(s): U. Tox and H. M. Steffen
Affiliation:
Keywords: Liver fibrosis, portal hypertension, renin-angiotensin-aldosterone system, AT1 receptor blocker, ACE inhibitor, aldosterone antagonist, aliskiren
Abstract: Morbidity and mortality of chronic liver disease are primarily caused by liver cirrhosis and portal hypertension, both of them secondary disorders of progressive liver fibrosis. The main fibrogenic cell type in the liver, the hepatic stellate cell (HSC), is activated and stimulated by several factors, among which the renin-angiotensin-aldosterone system (RAAS) plays a major role. Angiotensin II induces various profibrotic pathways via the angiotensin II receptor type 1 (AT1 receptor) not only in heart and kidney, but also in liver tissue. Stimulation of the AT1 receptor promotes the transformation of the quiescent HSC into the myofibroblast like activated HSC and the synthesis of transforming growth factor- 1 (TGF-7bgr;), the major profibrotic cytokine in the liver. In addition, aldosterone has been suggested to induce profibrotic effects in chronic heart and liver disease. This review focuses on the concept that inhibitors of the RAAS retard or even reverse liver fibrosis and reduce portal hypertension. Angiotensin converting enzyme (ACE) inhibitors, AT1 receptor antagonists, and aldosterone antagonists have been demonstrated to reduce the proliferation of HSC, to decrease the synthesis of profibrotic molecules, and to have the potential to improve liver fibrosis. However, side-effects such as systemic hypotension may impair the clinical application of RAAS inhibitors in patients with liver cirrhosis and portal hypertension. Also, efficacy may be limited by the downregulation of AT1 receptors in advanced fibrosis, which has been observed in animal and human studies. Randomized clinical studies are essential to evaluate, whether this approach is beneficial in patients with chronic liver disease and progressive fibrosis.
Export Options
About this article
Cite this article as:
Tox U. and Steffen M. H., Impact of Inhibitors of the Renin-Angiotensin-Aldosterone System on Liver Fibrosis and Portal Hypertension, Current Medicinal Chemistry 2006; 13 (30) . https://dx.doi.org/10.2174/092986706779026138
DOI https://dx.doi.org/10.2174/092986706779026138 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phospholipase A2 Inhibitors as Potential Anti-Inflammatory Agents
Current Pharmaceutical Design Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis
Current Pharmaceutical Design Pathophysiology of Sepsis and Recent Patents on the Diagnosis, Treatment and Prophylaxis for Sepsis
Recent Patents on Inflammation & Allergy Drug Discovery Current Key Points in Management for Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets A Critical Review on the Unexplored Therapeutic Treasure of Himalayan Ayurvedic Drug Daruharidra (<i>Berberis Aristata</i>)
Current Traditional Medicine Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Participation of the Cannabinoid System in the Regulation of Emotional- Like Behaviour
Current Pharmaceutical Design Hydrogen Sulfide and its Modulation in Arterial Hypertension and Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of Infrared Spectroscopy in Medicinal Plants Research in Pakistan
Current Bioactive Compounds Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews